Elevation Oncology Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Elevation Oncology disminuyan a un ritmo anual de 10.5%, mientras que sus ingresos anuales crecerán a un ritmo de 80.1% por año. Se espera que el BPA crezca en un 2.5% al año.

Información clave

-16.0%

Tasa de crecimiento de los beneficios

-2.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	81.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	28 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ELEV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-83	-88	-99	6
12/31/2025	N/A	-60	-55	-58	7
12/31/2024	N/A	-46	-39	-41	7
6/30/2024	N/A	-40	-43	-43	N/A
3/31/2024	N/A	-39	-49	-49	N/A
12/31/2023	N/A	-46	-56	-56	N/A
9/30/2023	N/A	-57	-62	-62	N/A
6/30/2023	N/A	-85	-93	-93	N/A
3/31/2023	N/A	-95	-88	-88	N/A
12/31/2022	N/A	-95	-86	-85	N/A
9/30/2022	N/A	-86	-77	-77	N/A
6/30/2022	N/A	-59	-40	-40	N/A
3/31/2022	N/A	-44	-35	-35	N/A
12/31/2021	N/A	-32	-30	-30	N/A
9/30/2021	N/A	-31	-25	-25	N/A
6/30/2021	N/A	-22	-22	-21	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-17	-12	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ELEV siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ELEV siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ELEV siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ELEV no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ELEV no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ELEV se prevé que sea elevada dentro de 3 años.

Elevation Oncology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 24% to US$6.00

Price target decreased by 19% to US$4.17

Price target decreased to US$5.17

Recent updates

Elevation Oncology Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirement

New minor risk - Market cap size

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento